A Phase 3, Multicenter, Open-Label, Randomized Study Comparing The Efficacy And Safety Of AG-221 (CC-90007) Versus Conventional Care Regimens In Older Subjects With Late Stage Acute Myeloid Leukemia Harboring An Isocitrate Dehydrogenase 2 Mutation
You are being asked to take part in this study because you are at least 60 years old and have acute myelogenous leukemia (AML) that has either relapsed (has returned) or is refractory (has not responded to treatment) and have an IDH2 gene mutation. The goal of this clinical research study is to learn how well AG-221 (enasidenib) may control AML when compared to standard of care treatment in patients over 60 who have an IDH2 gene mutation.
Treatment Location: N/A
IRB Review and Approval Date: 05/19/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: